On July 1, 2026, Insilico Medicine (Insilico),  a clinical-stage biotechnology company powered by generative artificial intelligence and automation, announced a strategic collaboration agreement with Takeda to use Insilico’s proprietary end-to-end platform, Pharma.AI, to advance drug candidates across various therapeutic areas, with a potential initial value of $600 million. Insilico will lead drug discovery, while Takeda will further development, including advancing candidates past clinical trials.

Under the agreement, Insilico will receive approximately $60 million in project initiation fees and near-term payments, and is eligible for milestone payments and tiered royalties on future sales. Takeda will be granted exclusive worldwide rights to develop, manufacture, and commercialize novel therapeutics selected through the collaboration.

The Wilson Sonsini team that advised Insilico on the transaction includes Alex Key, Kexi Wang, Kimberly Parry, and Joshua Gruenspecht.

For more information, please see Insilico's news release. Additional coverage can be found on The Wall Street Journal, CNBC, and MSN.